132 related articles for article (PubMed ID: 38856639)
1. FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer.
Casak SJ; Kumar V; Song C; Yuan M; Amatya AK; Cheng J; Mishra-Kalyani PS; Tang S; Lemery SJ; Auth D; Davis G; Kluetz PG; Pazdur R; Fashoyin-Aje LA
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38856639
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK; Ueno M; Yoo C; Finn RS; Furuse J; Ren Z; Yau T; Klümpen HJ; Chan SL; Ozaka M; Verslype C; Bouattour M; Park JO; Barajas O; Pelzer U; Valle JW; Yu L; Malhotra U; Siegel AB; Edeline J; Vogel A;
Lancet; 2023 Jun; 401(10391):1853-1865. PubMed ID: 37075781
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY; He AR; Bouattour M; Okusaka T; Qin S; Chen LT; Kitano M; Lee CK; Kim JW; Chen MH; Suksombooncharoen T; Ikeda M; Lee MA; Chen JS; Potemski P; Burris HA; Ostwal V; Tanasanvimon S; Morizane C; Zaucha RE; McNamara MG; Avallone A; Cundom JE; Breder V; Tan B; Shimizu S; Tougeron D; Evesque L; Petrova M; Zhen DB; Gillmore R; Gupta VG; Dayyani F; Park JO; Buchschacher GL; Rey F; Kim H; Wang J; Morgan C; Rokutanda N; Żotkiewicz M; Vogel A; Valle JW
Lancet Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38823398
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab: A Review in Advanced Biliary Tract Cancer.
Fung S; Syed YY
Target Oncol; 2023 Nov; 18(6):965-972. PubMed ID: 37943483
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Oh DY; Ruth He A; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Ah Lee M; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; He P; Kurland JF; Cohen G; Valle JW
NEJM Evid; 2022 Aug; 1(8):EVIDoa2200015. PubMed ID: 38319896
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Oh DY; Lee KH; Lee DW; Yoon J; Kim TY; Bang JH; Nam AR; Oh KS; Kim JM; Lee Y; Guthrie V; McCoon P; Li W; Wu S; Zhang Q; Rebelatto MC; Kim JW
Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):522-532. PubMed ID: 35278356
[TBL] [Abstract][Full Text] [Related]
10. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY; He AR; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Lee MA; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; Żotkiewicz M; Kurland JF; Cohen G; Valle JW
Future Oncol; 2023 Nov; 19(34):2277-2289. PubMed ID: 37746835
[TBL] [Abstract][Full Text] [Related]
11. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
Inokuchi J; Eto M
Cancer Manag Res; 2019; 11():4519-4528. PubMed ID: 31191013
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Pai-Scherf L; Blumenthal GM; Li H; Subramaniam S; Mishra-Kalyani PS; He K; Zhao H; Yu J; Paciga M; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Nov; 22(11):1392-1399. PubMed ID: 28835513
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date.
Storandt MH; Jin Z; Mahipal A
Onco Targets Ther; 2024; 17():383-394. PubMed ID: 38774819
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
Olkus A; Tomczak A; Berger AK; Rauber C; Puchas P; Wehling C; Longerich T; Mehrabi A; Chang DH; Liermann J; Schäfer S; Pfeiffenberger J; Jäger D; Michl P; Springfeld C; Dill MT
Target Oncol; 2024 Mar; 19(2):213-221. PubMed ID: 38416377
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Rimini M; Fornaro L; Lonardi S; Niger M; Lavacchi D; Pressiani T; Lucchetti J; Giordano G; Pretta A; Tamburini E; Pirrone C; Rapposelli IG; Diana A; Martinelli E; Garajová I; Simionato F; Schirripa M; Formica V; Vivaldi C; Caliman E; Rizzato MD; Zanuso V; Nichetti F; Angotti L; Landriscina M; Scartozzi M; Ramundo M; Pastorino A; Daniele B; Cornara N; Persano M; Gusmaroli E; Cerantola R; Salani F; Ratti F; Aldrighetti L; Cascinu S; Rimassa L; Antonuzzo L; Casadei-Gardini A
Liver Int; 2023 Aug; 43(8):1803-1812. PubMed ID: 37452505
[TBL] [Abstract][Full Text] [Related]
18. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
Monge C; Xie C; Myojin Y; Coffman-D'Annibale KL; Hrones D; Brar G; Wang S; Budhu A; Figg WD; Cam M; Finney R; Levy EB; Kleiner DE; Steinberg SM; Wang XW; Redd B; Wood BJ; Greten TF
Cancer Med; 2024 Feb; 13(3):e6912. PubMed ID: 38205877
[TBL] [Abstract][Full Text] [Related]
19. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
